LIGNOCAINE

Drug name: Lignocaine

Drug name: Lignocaine

Section 1. Drug absorption

The Lignocaine was synthesized for the first time with the name of xylocaine, in 1943 by Nils Lofgren. The drug Lignocaine is commonly used as an antiritmico agent but also as a local anesthetic. Lignocaine, used as a local anesthetic, works by blocking the stimulation of pain receptors, in fact, is often used for minor surgery. The Lignocaine is, however, also used in topically to relieve itching and burning.

For its anesthetic properties of the drug Lignocaine was mistakenly used as a cure for premature ejaculation, but not a specific and targeted drug treatment, did not, of course, the expected results, in fact, in many cases, Lignocaine, has also managed to worsen the sexual disorder (Quon & Fedder, 2011, pp. 121-29).

In fact, the drug Lignocaine, applied directly to the penis, has as a disadvantage to make the part in which the application was made totally insensitive. In addition, the Lignocaine when used as a treatment for premature ejaculation can cause severe irritation on the part of the penis treated (Geigle, 2001, pp. 45-59).

Section 2. Drug formulation and routes of administration

Lignocaine is normally available in two formulations throughout Australia. One of the formulation of Lignocaine is with the alcoholic and aqueous (5%) spray and the other formulation is with the mefenamic acid (500) mg. However, based on the studies, both these formulations are enough reliable for the medical purpose.

Lignocaine are more common in the elderly, in patients with heart failure, in the case of decreased cardiac output, decreased hepatic clearance of (Pfeifer et al., 1975). The most serious side effects are those neurological and cardiovascular (conduction block with cardiac arrest). The analysis of reported adverse reaction to local anaesthetics (Lignocaine, bupivacaine, mepivacaine, ropivacaine, levobupivacaine) from the centre of the French Pharma co-vigilance in the period 1995-2006, showed Lignocaine and bupivacaine as local anaesthetics most frequently involved in reactions toxicity (respectively 36.0% and 35.4% of reports). 

The most frequent adverse reaction was ineffective anaesthesia (absence of aesthetic block) (27.7%) followed by neurological side effects (22.1%), allergy (19.4%) and cardiovascular toxicity (15.3%).

At concentrations of Lignocaine of 2-5 mcg / ml, slightly increased cardiac output with increase of vascular tone which however does not determine significant changes in blood pressure. For higher concentrations, ranging from 5 to 10 mcg / ml increases the pressure inside the heart, contraction and scope myocardial and peripheral vasodilation appears. 

At concentrations in excess of 10 mcg / ml, the effects on the heart and intensify the patient undergoes obvious vasodilation and cardiovascular collapse (Gupta, et. al., 2011, pp. 68-70).

Section 3. Drug distribution

Drug distribution of Lignocaine and as a cure for premature ejaculation as anesthetic, should not be underestimated. In fact, numerous clinical studies have shown and proven, over and over again, countless, and not at all mild side effects of Lignocaine.

Therefore, those who make use of Lignocaine, considering it as a cure for premature ejaculation, need to know that the risks associated with Lignocaine is much higher than the potential benefits, even if the latter were to be ...